None listed
Conditions
Interventions
Intervention1: 0.1 ml (200µg)Alendronate Gel: At the experimental site, 0.1 ml (200µg) of Alendronate gel will be delivered to the osseous defect while the control site will receive 0.1 ml of Placeb
Reddy GT, Kumar PM, Veena KM. Formulation and evaluation of Alendronate sodium gel for the treatment of bone resorptive lesions in periodontitis. Drug Delivery 2005
12: 217-222.
Control Intervention1: 0.1 ml of Placebo, alendronate-free gel with identical basic composition.: At the experimental site, 0.1 ml (200µg) of Alendronate gel will be delivered to the os
12: 217-222.
Sponsors
PRINCIPAL INVESTIGATOR
Eligibility
Inclusion criteria
Inclusion criteria: a)Patient of either sex within the age group of 35-50 years. b)Systemically healthy patients. c)Clinical diagnosis of moderate generalized chronic periodontitis. d)Patients with probing depth >=5 mm or clinical attachment loss > 4 to 6 mm bilaterally as evidenced by clinical examination. e)Patients with vertical bone loss > 5mm as evidenced on IOPA radiograph. f)Patients with acceptable oral hygiene following Phase-I therapy.
Exclusion criteria
Exclusion criteria: a)Patients with presence of systemic conditions or disease affecting bone density e.g. Osteoporosis, Pagetâ??s disease. b)Patients with known or suspected allergy to Alendronate/ bisphosphonates group. c)Patients with Aggressive Periodontitis. d)Patients with horizontal bone loss. e)Patients without any contradictions for periodontal surgery. f)Patients with a history of drug intake that can affect bone metabolism in the past 6 months. E.g. NSAIDs. g)Patients who are current smokers, or ex smokers for less than five years. h)Pregnant or lactating females. i)Patients who are alcoholics. j)Immunocompromised patients. k)Patients using tobacco in any form. l)Patients with gross oral pathology, tumors which can alter the course of periodontal disease. m)Patients who have taken medications affecting periodontal status or has received periodontal therapy in the preceding six months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| â?¢To assess the bone regeneration in osseous defects clinically â?¢To assess the bone regeneration in osseous defects radiographicallyTimepoint: Recall Appointments at 1 month, 3 month, 6 month & 9 month post surgery intervals for post operative review and clinical and radiological assessment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Baseline clinical parameters like Bleeding on Probing, Gingival Index, Periodontal Probing Depth and Clinical Attachment Level of all the patients will be measured followed by radiographic assessment by intra-oral radiograph.Timepoint: Recall Appointments at 1 month, 3 month, 6 month & 9 month post surgery intervals for post operative review and clinical and radiological assessment. | — |
Countries
India
Contacts
Public ContactMAJ DR MUNISHWAR SINGH
Armed Forces Medical College
Outcome results
None listed